The National Primary Health Care Development Agency (NPHCDA)
says 8,439 persons across the country have reported mild side effects after
they received the AstraZeneca COVID-19 vaccine.
Faisal Shuaib, executive director of NPHCDA, disclosed this
in Abuja on Friday at a media briefing organised by the agency and the World
Health Organisation (WHO) to give an update on the status of COVID-19
vaccination in the country.
While noting that those who reported severe side effects
were less than 100, he said there has been no record of death or blood clots
associated with the distribution of the vaccine.
“Out of over a million persons given the Oxford/AstraZeneca COVID-19 vaccine in Nigeria, 8,439 persons have suffered mild adverse events following immunisation (AEFI), and 52 persons moderate to severe adverse events on receiving the jab,” Shuaib said.
“While the mild
reactions include body pains and swelling, the moderate to severe adverse
events presented were fever, vomiting, diarrhoea, headaches, dizziness and
allergic reactions.”
According to NAN, Shuaib listed the five states with the
highest records of side effects as follows: Kaduna (970), Cross River (859),
Yobe (541), Kebbi (511), and Lagos (448), adding that investigation is ongoing
to verify the nature of the symptoms.
The executive director, who noted that the government has
reviewed the timeframe for eligibility for the second dose in line with
recommendations by WHO, added that the plan is to ensure that the first phase
of vaccination is completed before the expiration date in July.
“Furthermore, as a
result of this overall programme review to meet the challenges of global
vaccine demand and supply mismatch, and the late commencement of the
vaccination in some states, we are expanding the eligibility period between the
first and second doses of the vaccine from 12 weeks to between eight to 12
weeks,” he said.
“This is still in line with the scientific recommendation
provided by the World Health Organisation’s Strategic Advisory Group of Experts
(SAGE on immunisation) that the two doses of the vaccine be given at an
interval of eight to 12 weeks.”
Nigeria has received close to 4.5 million doses of the
vaccine — 3.94 million delivered via the United Nations-led COVAX facility,
while others are donations from India and private organisations.
Rollout began on March 5, and according to NPHCDA, more than
one million Nigerians have received the first dose of the vaccine.
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com